ArticleGut2000
Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane.
Article in Gut, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 112 citations in OpenAlex.
- Autoantibodies in the follow-up of autoimmune hepatitis.Journal of translational autoimmunity · 2026Review
- Metabolic syndrome and its individual components but not MASLD are associated with advanced fibrosis in primary biliary cholangitis.Therapeutic advances in gastroenterology · 2026Article
- Article
- Early assessment of treatment response in primary biliary cholangitis: key to timely management.BMC gastroenterology · 2025Article
- Unmet needs in autoimmune liver diseases.Current opinion in immunology · 2025Review
- Exploring the Pathogenesis of Autoimmune Liver Diseases from the Heterogeneity of Target Cells.Journal of clinical and translational hepatology · 2024Review
- Neonatal Lupus presenting with neonatal hemochromatosis-like liver disease that responded to steroids: a case report.BMC pediatrics · 2022Article
- B cells in autoimmune hepatitis: bystanders or central players?Seminars in immunopathology · 2022Review
- Chinese medicine in the treatment of autoimmune hepatitis: Progress and future opportunities.Animal models and experimental medicine · 2022Review
- Autoimmmune hepatitis.Cellular & molecular immunology · 2022Review
- Impact of Antigen Presentation Mechanisms on Immune Response in Autoimmune Hepatitis.Frontiers in immunology · 2021Review
- The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases.Frontiers in immunology · 2021Review
- The Contribution of B Cells in Autoimmune Liver Diseases.Seminars in liver disease · 2019Review
- Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis.Frontiers in pediatrics · 2019Review
- Autoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance.Frontiers in immunology · 2018Review
- "Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis.International journal of molecular sciences · 2017Review
- Autoantibody profiles in autoimmune hepatitis and chronic hepatitis C identifies similarities in patients with severe disease.World journal of gastroenterology · 2017Article
- Immunopathogenic Mechanisms of Autoimmune Hepatitis: How Much Do We Know from Animal Models?International journal of molecular sciences · 2016Review
- Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics.World journal of gastroenterology · 2015Review
- Mechanisms of tissue injury in autoimmune liver diseases.Seminars in immunopathology · 2014Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver/kidney microsomal antibody type 1 (LKM1) is the marker of type 2 autoimmune hepatitis (AIH) and is detected in up to 6% of patients with hepatitis C virus (HCV) infection. It recognises linear and conformational epitopes of cytochrome P450IID6 (CYP2D6) and may have liver damaging activity, provided that CYP2D6 is accessible to effector mechanisms of autoimmune attack.
methodsThe presence of LKM1 in the plasma membrane was investigated by indirect immunofluorescence and confocal laser microscopy of isolated rat hepatocytes probed with 10 LKM1 positive sera (five from patients with AIH and five from patients with chronic HCV infection) and a rabbit polyclonal anti-CYP2D6 serum.
resultsSerum from both types of patient stained the plasma membrane of non-permeabilised cells, where the fluorescent signal could be visualised as discrete clumps. Conversely, permeabilised hepatocytes showed diffuse submembranous/cytoplasmic staining. Adsorption with recombinant CYP2D6 substantially reduced plasma membrane staining and LKM1 immunoblot reactivity. Plasma membrane staining of LKM1 colocalised with that of anti-CYP2D6. Immunoprecipitation experiments showed that a single 50 kDa protein recognised by anti-CYP2D6 can be isolated from the plasma membrane of intact hepatocytes.
conclusionsAIH and HCV related LKM1 recognise CYP2D6 exposed on the plasma membrane of isolated hepatocytes. This observation supports the notion that anti-CYP2D6 autoreactivity may be involved in the pathogenesis of liver damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.